1.Efficacy and safety of avatrombopag in the treatment of thrombocytopenia after umbilical cord blood transplantation.
Aijie HUANG ; Guangyu SUN ; Baolin TANG ; Yongsheng HAN ; Xiang WAN ; Wen YAO ; Kaidi SONG ; Yaxin CHENG ; Weiwei WU ; Meijuan TU ; Yue WU ; Tianzhong PAN ; Xiaoyu ZHU
Chinese Medical Journal 2025;138(9):1072-1083
BACKGROUND:
Delayed platelet engraftment is a common complication after umbilical cord blood transplantation (UCBT), and there is no standard therapy. Avatrombopag (AVA) is a second-generation thrombopoietin (TPO) receptor agonist (TPO-RA) that has shown efficacy in immune thrombocytopenia (ITP). However, few reports have focused on its efficacy in patients diagnosed with thrombocytopenia after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
METHODS:
We conducted a retrospective study at the First Affiliated Hospital of the University of Science and Technology of China to evaluate the efficacy of AVA as a first-line TPO-RA in 65 patients after UCBT; these patients were compared with 118 historical controls. Response rates, platelet counts, megakaryocyte counts in bone marrow, bleeding events, adverse events and survival rates were evaluated in this study. Platelet reconstitution differences were compared between different medication groups. Multivariable analysis was used to explore the independent beneficial factors for platelet implantation.
RESULTS:
Fifty-two patients were given AVA within 30 days post-UCBT, and the treatment was continued for more than 7 days to promote platelet engraftment (AVA group); the other 13 patients were given AVA for secondary failure of platelet recovery (SFPR group). The median time to platelet engraftment was shorter in the AVA group than in the historical control group (32.5 days vs . 38.0 days, Z = 2.095, P = 0.036). Among the 52 patients in the AVA group, 46 achieved an overall response (OR) (88.5%), and the cumulative incidence of OR was 91.9%. Patients treated with AVA only had a greater 60-day cumulative incidence of platelet engraftment than patients treated with recombinant human thrombopoietin (rhTPO) only or rhTPO combined with AVA (95.2% vs . 84.5% vs . 80.6%, P <0.001). Patients suffering from SFPR had a slightly better cumulative incidence of OR (100%, P = 0.104). Patients who initiated AVA treatment within 14 days post-UCBT had a better 60-day cumulative incidence of platelet engraftment than did those who received AVA after 14 days post-UCBT (96.6% vs . 73.9%, P = 0.003).
CONCLUSION
Compared with those in the historical control group, our results indicate that AVA could effectively promote platelet engraftment and recovery after UCBT, especially when used in the early period (≤14 days post-UCBT).
Humans
;
Female
;
Male
;
Thrombocytopenia/etiology*
;
Adult
;
Retrospective Studies
;
Cord Blood Stem Cell Transplantation/adverse effects*
;
Middle Aged
;
Adolescent
;
Young Adult
;
Thiazoles/adverse effects*
;
Platelet Count
;
Receptors, Thrombopoietin/agonists*
;
Child
;
Thiophenes
2.Behavioral Economic Analysis for Low-Value Care in Oncology
Hongqiu ZHENG ; Hongjie CHU ; Genyong ZUO ; Baolin CHENG ; Zhiyuan HOU
Chinese Health Economics 2025;44(9):1-4
Objective:Drawing upon behavioral economics theory,it aims to elucidate the irrational decision-making mechanisms and systematic governance strategies driving low-value care in oncology,optimize healthcare resource allocation and enhance service quality.Methods:Centered on the dual-system theory framework,the behavioral economics principles of loss aversion,anchoring effects,and intertemporal choice are integrated to develop a physician-patient shared decision-making model spanning the entire cancer care continuum(screening,diagnosis,treatment,rehabilitation).Results:Low-value oncology care are jointly driven by physicians' defensive psychology,patients'loss aversion preferences,and socio-cultural pressures.Conclusion:Multidimensional interventions,such as predefining high-value care pathways,establishing negative lists to constrain low-value supply,reforming payment mechanisms,and implementing targeted health education,can effectively disrupt the"cognitivebias-behavioral inertia"loop and improve the efficiency of resource allocation in cancer diagnosis and treatment.
3.Behavioral Economic Analysis for Low-Value Care in Oncology
Hongqiu ZHENG ; Hongjie CHU ; Genyong ZUO ; Baolin CHENG ; Zhiyuan HOU
Chinese Health Economics 2025;44(9):1-4
Objective:Drawing upon behavioral economics theory,it aims to elucidate the irrational decision-making mechanisms and systematic governance strategies driving low-value care in oncology,optimize healthcare resource allocation and enhance service quality.Methods:Centered on the dual-system theory framework,the behavioral economics principles of loss aversion,anchoring effects,and intertemporal choice are integrated to develop a physician-patient shared decision-making model spanning the entire cancer care continuum(screening,diagnosis,treatment,rehabilitation).Results:Low-value oncology care are jointly driven by physicians' defensive psychology,patients'loss aversion preferences,and socio-cultural pressures.Conclusion:Multidimensional interventions,such as predefining high-value care pathways,establishing negative lists to constrain low-value supply,reforming payment mechanisms,and implementing targeted health education,can effectively disrupt the"cognitivebias-behavioral inertia"loop and improve the efficiency of resource allocation in cancer diagnosis and treatment.
4.Advances on molecular testing for cervical lymph node metastasis of thyroid cancer
Baolin CHEN ; Zhongliang YAN ; Chengmin LUO ; Yuxiang BAO ; Xiaoming CHENG ; Junyuan LYU
International Journal of Surgery 2024;51(1):48-53
Cervical lymph node metastasis in thyroid cancer is closely related to the disease recurrence and prognosis of patients. Accurate judgment of lymph node metastasis is vital for tumor stage and treatment in patients with thyroid cancer, which can effectively improve the prognosis of patients. However, preoperative detection of cervical lymph node metastasis is the key points and difficulties in individualized treatment of thyroid cancer. Currently, fine needle aspiration washout fluid thyroglobulin is often used to assess cervical lymph node metastasis of differentiated thyroid cancer preoperatively, and it has a higher diagnostic efficacy. The continuous exploration and application of tumor markers and emerging biomarkers have provided new perspectives for the preoperative diagnosis of lymph node metastasis in thyroid cancer. As a new non-invasive detection technique, liquid biopsy is convenient to obtain samples and has broad clinical application in early diagnosis of cervical lymph node metastasis of thyroid cancer. In addition, the analysis and application of liquid biopsy biomarkers will help the development of clinical diagnosis and treatment strategies, and provide the possibility of early precision therapy for thyroid cancer patients. This review summarizes current research surrounding the molecular markers related to cervical lymph node metastasis of thyroid cancer.
5.Role of ferroptosis in hepatic ischemia-reperfusion injury
Jiaxin LIANG ; Baolin XU ; Yu CHENG ; Yong WEI
Journal of Clinical Hepatology 2024;40(8):1693-1698
Ferroptosis is a new type of regulatory cell death and is mainly caused by changes in intracellular iron homeostasis due to various inducers,which promotes the occurrence of iron ion-dependent lipid peroxidation,thereby leading to the accumulation of toxic lipid peroxides and finally resulting in cell death.Hepatic ischemia-reperfusion injury is a common and serious complication after liver surgery,with the main mechanisms of anaerobic respiration,mitochondrial injury,oxidative stress response,inflammatory response,calcium overload,and microcirculation dysfunction.This article introduces the concepts and mechanisms of ferroptosis and hepatic ischemia-reperfusion injury and summarizes some related treatment strategies,so as to provide a reference for exploring new treatment methods for hepatic ischemia-reperfusion injury.
6.Establishment of Specific Chromatogram and Thin-layer Identification Method for Kaixinsan
Wenya GAO ; Min FENG ; Chang GAO ; Haiyu ZHAO ; Yanyan ZHOU ; Hongjie WANG ; Ruipeng YU ; Yipeng ZHAO ; Lili ZHANG ; Yanqing GAO ; Yanhong XIAO ; Cuina CHENG ; Xiaolu WEI ; Nan SI ; Baolin BIAN
Chinese Journal of Experimental Traditional Medical Formulae 2023;29(13):37-44
ObjectiveTo establish the specific chromatogram and thin layer chromatography(TLC) identification method of Kaixinsan(KXS) samples, in order to clarify the key quality attributes and provide reference for the quality evaluation of KXS. MethodHigh performance liquid chromatography(HPLC) specific chromatogram of KXS was developed with YMC Hydrosphere C18 column(4.6 mm×250 mm, 5 μm), the mobile phase was acetonitrile(A)-0.2% formic acid aqueous solution(B) for gradient elution(0-15 min, 2%-20%A; 15-25 min, 20%-25%A; 25-30 min, 25%-30%A; 30-45 min, 30%-31%A; 45-50 min, 31%-44%A; 50-65 min, 44%-45%A; 65-73 min, 45%-75%A; 73-95 min, 75%-100%A; 95-105 min, 100%A; 105-105.1 min, 100%-2%A; 105.1-120 min, 2%A), the detection wavelength was 320 nm. Ultra high performance liquid chromatography-linear ion trap-electrostatic field orbitrap mass spectrometry(UHPLC-LTQ-Orbitrap MS) was used to identify the chemical components of KXS with electrospray ionization(ESI), negative ion mode and scanning range of m/z 50-2 000. TLC identification methods for Poria and Ginseng Radix et Rhizoma in KXS were established. ResultThere were 11 common peaks in the specific chromatogram of KXS, attributed to Polygalae Radix, Poria and Acori Tatarinowii Rhizoma. Taking peak 9(α-asarone) as the reference peak, the relative standard deviations of the retention times of 15 batches of KXS samples were<0.2%. A total of 34 compounds were identified by UHPLC-LTQ-Orbitrap MS, including terpenoids, phenylpropanoids, oligosaccharides and ketones. The established TLC had good separation and was rapid, reliable, simple, feasible, suitable for the identification of Poria and Ginseng Radix et Rhizoma in KXS. ConclusionThe specific chromatogram and TLC of KXS are stable and reproducible. The material basis of KXS is basically clarified by MS, which can provide a reference for the development and quality control of KXS.
7.The role of competitive endogenous RNA in the development of cholangiocarcinoma
Baolin XU ; Yu CHENG ; Yong WEI
Journal of Clinical Hepatology 2022;38(11):2659-2662
Cholangiocarcinoma is a highly malignant tumor with a poor prognosis, limited treatment options, and complicated pathogenesis. Competitive endogenous RNA is a kind of transcripts that can competitively bind miRNA, including long non-coding RNA and circular RNA. Competitive endogenous RNA is known to be involved in a variety of tumors. It can modulate the occurrence and development of cholangiocarcinoma by regulating the biological behavior, cell metabolism, inflammatory process and epithelial-mesenchymal transition of cholangiocarcinoma cells. Here we review recent research progress on the role of long non-coding RNA and circular RNA in cholangiocarcinoma to help better understand the pathogenesis of cholangiocarcinoma.
8.Research progress of mitochondrial dysfunction in pancreatic diseases
Yonglang CHENG ; Meizhou HUANG ; Hao CHEN ; Baolin QIAN ; Zhiwei HUANG ; Wenguang FU
Chinese Journal of Hepatobiliary Surgery 2021;27(8):637-640
Mitochondrial dysfunction is closely related to the occurrence and development of benign and malignant diseases of the pancreas. Mitochondrial membrane of the respiratory chain electron transfer and energy transfer plays an important role in maintaining normal cellular function. When the respiratory chain was disrupted, the oxidative stress was increased in the cell, and produced a large number of oxide intermediate products which target mitochondrial protein, DNA, etc, lead to mitochondrial dysfunction finally induced acute pancreatitis, pancreatic cancer and other diseases. In addition, mitochondrial homeostasis plays an indispensable role in maintaining the normal function of islet cells. This paper reviewed the research status of mitochondrial dysfunction in pancreatic diseases.
9.A New Generation of Radiotherapy Technology-Flash Radiotherapy.
Cheng WU ; Jia SONG ; Bin YIN ; Gaolong ZHANG ; Haibo LIN ; Chunfeng FANG ; Tao YANG ; Baolin QU ; Shouping XU
Chinese Journal of Medical Instrumentation 2020;44(6):508-512
Flash radiotherapy is a kind of radiotherapy method using ultra-high dose rate radiation. Compared with the traditional dose rate radiotherapy, it has unique radiobiological advantages. In this paper, the principle of flash radiotherapy, the process and results of biological experiments are summarized. At the same time, the advantages and challenges of flash radiotherapy are analyzed, and the future clinical application is prospected.
Radiotherapy/methods*
;
Radiotherapy Dosage
;
Technology

Result Analysis
Print
Save
E-mail